General session II and award ceremony I

 General hepatology
 Webcasted session

Main Plenary
English
Science/Research
13 April 2018 08:30 - 10:30


Presentations

GS-007 First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry
Thomas Berg , Germany
13 April 2018 08:30 - 08:45

Abstract
GS-008 Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: An extended 5-year follow-up
Jeong-Hoon Lee , Korea, Rep. of South
13 April 2018 08:45 - 09:00

Abstract
GS-009 MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
Stephen Harrison , United States
13 April 2018 09:00 - 09:15

Abstract
Recognition Award Presentation
Michael P. Manns , Germany
13 April 2018 09:15 - 09:20

Recognition Awardee
Mario Umberto Mondelli , Italy
13 April 2018 09:20 - 09:25

Recognition Award Presentation
Daniel Shouval , Israel
13 April 2018 09:25 - 09:30

Recognition Awardee
Didier SAMUEL , France
13 April 2018 09:30 - 09:35

International Recognition Award Presentation
Marc Ghany , United States
13 April 2018 09:35 - 09:40

International Recognition Awardee
Anna LOK , United States
13 April 2018 09:40 - 09:45

GS-010 HEPAHEALTH: The Burden of liver disease in Europe
Helena Cortez-Pinto , Portugal
13 April 2018 09:45 - 10:00

GS-011 Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
Gideon Hirschfield , United Kingdom
13 April 2018 10:00 - 10:15

Abstract
GS-012 Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study
Tarik Asselah , France
13 April 2018 10:15 - 10:30

Abstract